Novartis announces acquisition of CoStim Pharmaceuticals - 0 views
-
Alex Parker on 19 Feb 14Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.